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Abstract 
Decorin, an archetypical member of the small leucine-rich proteoglycan gene family, has a broad 
binding repertory that encompasses matrix structural components such as collagens, and growth 
factors, particularly those belonging to the TGFβ ligand superfamily. Within the tumor 
microenvironment, stromal decorin has an inherent proclivity to directly bind and downregulate several 
receptor tyrosine kinases, which are often overexpressed in cancer cells. The decorin interactome 
commands a powerful anti-tumorigenic signal by potently repressing and attenuating tumor cell 
proliferation, survival, migration, and angiogenesis. It also regulates key downstream signaling 
processes indirectly by sequestering growth factors or directly via receptor tyrosine kinase 
antagonism. We propose that decorin can be considered a “guardian from the matrix” because of its 
innate ability to oppose pro-tumorigenic cues.  
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Introduction 
Neoplastic growth has long been viewed in the paradigm of activating mutations in oncogenes and 
silencing of tumor suppressor genes that, collectively over time, confer selective advantages to 
fundamental cellular processes such as cell proliferation, survival, migration, and metastasis. 
However, over a relatively short period of time, the profound importance of the surrounding tumor 
stroma, encompassing that of abnormal synthesis and deposition of several proteoglycans, began to 
emerge as an active participant in coordinating many aspects of tumor growth and progression. 
Indeed, an early defining histopathological feature of certain carcinomas is the presence of a strong 
desmoplastic reaction surrounding the tumor proper which is inherently enriched in various 
proteoglycan species1,2. 
Decorin represents a prototypical member of the small leucine-rich proteoglycan (SLRP) gene 
family that houses 18 distinct members segregating into five discrete classes with sequence 
conservation across multiple species3. Decorin contains a single glycosaminoglycan (GAG) chain 
composed of either dermatan or chondroitin sulfate and 12 leucine-rich repeats comprising the protein 
core. Decorin is a stromal proteoglycan synthesized chiefly by fibroblasts, stressed vascular 
endothelial cells, and smooth muscle cells. Initially decorin was named for and characterized by its 
high affinity interaction with collagen fibers and for subsequent regulation of collagen fibrillogenesis4-7. 
It was subsequently discovered that decorin sequesters multiple growth factors, such as TGFβ1 and 
directly antagonizes several members of the receptor tyrosine kinase (RTK) family, including the 
epidermal growth factor receptor (EGFR), the insulin-like growth factor receptor I (IGF-IR) and the 
hepatocyte growth factor receptor (Met)1 (Fig. 1). Consequently, these latter bioactivities have been 
attributed to evoke a potent tumor repressive property. The unique nature of this repressive activity is 
provided by fact that it functions wholly within the extracellular matrix to attenuate, in an integrated 
and protracted fashion, key pro-survival, migratory, proliferative, and angiogenic signaling pathways2. 
In a novel discovery, decorin has been implicated in modulating the inflammatory response as it 
pertains to cancer progression via engagement of Toll-like receptors8. Moreover, reduced decorin 
within the tumor stroma has been established as a poor prognosticator of invasive breast cancer and 
in mouse models of spontaneous breast cancer with mammary gland carcinogenesis2. Endogenously, 
certain neoplasms have a proclivity to hypermethylate the decorin promoter, effectively silencing 
expression to allow for tumor progression2,9. Thus, loss of decorin expression may also favor tumor 
growth. 
In this review, we propose the concept of decorin as a guardian from the matrix, that is, a powerful 
endogenous tumor repressor acting in a paracrine fashion to limit tumor growth and angiogenesis.  
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Decorin Modulates Tumor Inflammatory Properties of the Stroma 
A rapidly emerging hallmark of cancer involves the inflammatory process as an active and critical 
participant in tumorigenesis10. Several articles have been published to indicate an immunomodulatory 
role of decorin to recruit monocytes to injury sites through inducing MCP-111, inhibiting apoptotic death 
of macrophages12, and modulating allergen-induced asthma13. A recently identified mechanism has 
been elucidated that links decorin, inflammation, and tumor growth8. This entails direct binding of 
soluble decorin to Toll-like receptors (TLR) 2 and 4 on macrophages. This leads to enhanced 
production of the pro-inflammatory protein programmed cell death 4 (PDCD4) and of the oncomir 
miR-21 causing stabilization and increased translation of PDCD4. The increased abundance of 
PDCD4 concurrently causes a decrease of anti-inflammatory cytokines such as interleukin-10 (IL-10) 
(Fig. 2). As an endogenous inhibitor of TGFβ1 by sequestration (Fig. 1) decorin also attenuates  the 
TGFβ1 signaling pathways thereby further curbing tumor growth and inflammation8. Thus, by 
antagonizing TGFβ1, decorin circumvents PDCD4 translational repression to generate a more pro-
inflammatory tumor microenvironment. It also induces the synthesis of pro-inflammatory modulators 
(TNFα, IL-12b) for the suppression of tumorigenic growth. It is important to note that TNFα is a 
binding partner for decorin14 (Fig 1) and shows a moderate affinity for this ligand, thus highlighting an 
important regulatory function to further fine tune TNFα activities.  
Recent experiments utilizing an animal model of delayed-type hypersensitivity in decorin-null mice 
are also supportive of a role of decorin for stimulating a more pro-inflammatory environment15. In this 
setting, lack of decorin is associated with reduced TNFα levels and increased expression of leukocyte 
adhesion molecules coincident with an increased adherence of leukocytes to the endothelium15. 
Finally, the closest relative of decorin, biglycan, has been previously shown to modulate immune 
responses16,17 by acting as an endogenous ligand for TLR-2/4 to increase pro-inflammatory signals. 
Thus, these studies offer a new functional paradigm for SLRPs and inflammation.  
 
Decorin Curbs the Lethality of the Tumor Niche by Directly Sequestering a Multitude of 
Growth Factors and Structural Components  
Decorin has exquisite binding affinities for members of the TGFβ superfamily (Fig.1) including TGFβ1, 
TGFβ2, and myostatin1,2, and through this interaction, can effectively trap ligands within the matrix 
and indirectly attenuate downstream signaling pathways mediated by the TGFβ receptor complex, as 
recently shown, for instance, in a mouse model of hepatic fibrosis18. However, bone-derived decorin 
seems to enhance TGFβ activity19. This has broad implications on tumorigenicity since it can 
advocate tumor immunosuppression and growth retardation20. However, it is not known if decorin 
influences assembly of the large latent TGFβ1 complex on collagen fibers. In the case of myostatin, 
decorin sequestration quenches myostatin growth inhibitory effects and thus promotes myoblastic 
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growth in vitro21. In an analogous antagonistic activity, direct sequestration of platelet derived growth 
factor (PDGF) results in a potent decrease of PDGF-dependent phosphorylation of PDGF receptor 
and attenuation of PDGF-evoked cellular migration22. 
Decorin binds to low density lipoprotein receptor related protein 1 (LRP-1) and causes endocytosis 
of the complex leading to PI3K activation and indirect crosstalk and modulation of TGFβ signaling via 
Smad 2/3/723. Although the interaction with LRP-1 has not yet been evaluated in cancer models, but it 
could have implications for tumor cell bioenergetics.  
Another binding partner of decorin is Wnt-1 induced secreted protein 1 (WISP-1), a protein mainly 
confined to the stroma of colon tumors24. Decorin binding to WISP-1 results in an inhibition of WISP-1 
interactions with other partners, thus suggesting a regulatory function of decorin in Wnt signaling24. It 
is not known if WISP-1 activity is further modulated or antagonized, in either a Wnt-1 dependent or 
independent manner, by decorin in colon tumors. Notably, decorin downregulates β-catenin in a non-
canonical way following binding to Met25, and decorin-null mice have increased β-catenin levels in the 
intestinal epithelium26. 
In addition to the aforementioned interactions and attenuation of growth factors by direct binding, 
decorin also binds a multitude of structural components within the extracellular matrix, particularly 
numerous collagen molecules, tenascin X27 and elastin28 (Fig. 1). Aside from binding fibrillar collagens 
I, II and III, decorin also binds saturably to collagen XIV. Thus, decorin may mediate binding to fibril-
forming collagens while simultaneously affecting collagen XIV biology. Analyses of the 
supramolecular composition of collagen VI complexes have determined that decorin and matrilin 
directly bind to link collagen VI to either aggrecan or collagen type II fibrils29. Taken together, it seems 
plausible that decorin can certainly participate in regulating the desmoplastic reaction and higher-
order matrix structure formation in the tumor stroma.  The abundant presence of decorin in the tumor 
stroma of solid tumors has been proposed to represent a negative feedback loop on the activity of 
adjacent RTKs expressed by the growing malignant cells1. 
 
Decorin is an Endogenous Pan-Receptor Tyrosine Kinase Inhibitor 
The initial finding that decorin bound with avid affinity to RTKs (Fig. 1) heralded a paradigm shift in the 
study of SLRPs and their contributions to cancer biology. EGFR was the first RTK discovered to bind 
decorin30 and was considered the primary target of decorin in various types of cancer cells2 for it 
triggered dimerization, internalization via caveosomes and ultimately degradation of the receptor 
complex within lysosomes31 which presumably terminates EGFR signaling. This is in contrast to EGF-
EGFR complexes competent to signal from endosomes following internalization where EGF is still 
capable of maximally stimulating tyrosine phosphorylation. Further, this stimulation engaged several 
signaling pathways, such as PLC-γ1, which is required for cell motility32. However, it is currently 
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unknown if decorin is proficient to stimulate signaling post-internalization in an analogous fashion to 
that of EGF.  
Systemic delivery of decorin or viral vectors expressing decorin affects the growth of several types 
of solid cancers where RTKs play key roles33-36. Paramount to this feature is the ability of decorin to 
compete off EGF and exert a potent physiological downregulation of the receptor at the cell surface of 
tumor cells2. However in 2009, a new target of decorin was discovered via the utilization of an RTK 
phosphor-tyrosine array, which clearly demonstrated a rapid burst of phosphorylation of Met37. It was 
further shown that Met is the main target of decorin in HeLa cells since inhibition of the kinase domain 
of EGFR with the small molecule inhibitor AG1478 or with the monoclonal blocking antibody, mAb425, 
did not block the downregulation of met evoked by decorin. Moreover, Met exhibits a higher binding 
affinity for decorin when compared to that of EGFR37.  
 It is a curious biologic feature of decorin to evoke differential phosphorylation signatures in EGFR 
and Met upon binding. This might reflect altered structural conformations of the receptors post-binding 
relative to the active conformation the receptor adopts after binding natural ligands. EGFR, for 
example, undergoes rapid phosphorylation to stimulate the MAPK signaling cascade, which 
paradoxically aids in cell cycle arrest and caspase-3 activation38, despite total EGFR levels 
decreasing by up to 50%2. Further proof-of-concept for this phenomenon involves Met. A rapid burst 
of phosphorylation along the tyrosine residues of the intracellular tails of Met ensues and lasts for up 
to 30 minutes whereupon increased phospho-Y1003 recruits the E3 ubiquitin ligase c-Cbl for receptor 
internalization and degradation37. It is possible these signatures, particularly that of Met, has biological 
significance to convey the properties of decorin bioactivity. However, at this time, experimental 
evidence to evaluate these differential phosphorylation patterns is lacking but would be essential to 
gain a more mechanistic understanding into the biology of decorin. This is of essential importance 
considering the lack of endogenous ligands for Met, which, at present, only include hepatocyte growth 
factor (HGF), internalin B, and decorin37,39. 
 Along these same lines, engagement of HGF with Met induces association of the receptor 
complex with clathrin coated pits40 in HeLa cells for endosomal sorting and eventual recycling to the 
plasma membrane. However, this is not the case for decorin since this drives caveolin-1 to associate 
with Met40 and concomitant lysosomal degradation in the same fashion as EGFR. Clearly, the 
differential phosphorylation patterns are encoding messages pertinent for decorin activity to 
selectively dictate finite biological outcomes. 
 Additional members of the Erb family of RTKs are also affected by decorin via degradation and 
signal suppression including ErbB2 and ErbB4, presumably via titration of EGFR away from functional 
signaling complexes composed of ErbB2 or ErbB4 heterodimers. However, new findings indicate a 
direct antagonism of the ErbB4 signaling by decorin41. During scar tissue repair in the central nervous 
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system, employment of small molecule inhibitors and siRNA specific for ErbB4 also blocks the 
decorin-mediated downregulation of semaphorin 3A, a target of ErbB4 activity41.  
 Opposing roles of decorin in the signaling cascades of endothelial cells have also been 
documented. Since decorin binds collagen with nanomolar affinity, it has been reported that an 
interaction among α2β1 integrin, collagen type I, and decorin increases endothelial cell migration by 
enhancing integrin-collagen interactions42. However, VEGF-R2 has been reported to be antagonized 
by decorin and more specifically via an engineered fragment encoding LRR5 via downstream 
attenuation of ERK1/2 signaling in human extravillous trophoblastic (EVT) cells43. 
 A recurring theme concerning this form of receptor antagonism is the concept of receptor 
internalization and degradation evoked by decorin for most of the RTKs studied so far. However, this 
is not the case for IGF-IR where decorin binds to and attenuates downstream signaling of IRS-1 and 
blunts IGF-I activation of Akt and ERK, and p70S6K culminating in a migratory block44. In this case, 
decorin does not promote association of IGF-IR with caveolin-1 but is capable of preventing IGF-I 
from localizing IGF-IR to caveosomes. Subsequently, this receptor complex is not internalized or 
degraded in cellular models of urinary bladder carcinoma44. In contrast, in other cellular systems using 
non transformed cells decorin seems to be an agonist of IGF-IR45,46. 
 Collectively, decorin can be considered as an endogenous matrix-centric pan RTK inhibitor that 
exhibits hierarchical binding affinities for various RTKs expressed at a given time by a tumor cell. This 
might aid in cross-talk signal integration as decorin would be able to bind multiple receptors with 
varying kinetics as a mechanism to subdue growth signals for tumor growth arrest. Further, a common 
thread uniting these receptors, with the exception of α2β1 integrin, is the inclusion of Ig-like modules 
in their ectodomain. It is possible that decorin has an inherent ability to bind all receptors harboring 
this particular domain. However, these binding events and potential biological outputs have not yet 
been experimentally evaluated.  
 
Decorin Antagonizes Tumorigenesis by Attenuating Multiple Signaling Pathways 
Robust and high-affinity binding concurrent with rapid receptor internalization and degradation 
underlay the initial events for decorin-mediated tumor growth repression vis-á-vis broad RTK 
antagonism (Fig. 2). Subsequent to this binding, a potent attenuation of multiple pathways 
coordinating proliferation, survival, and angiogenesis ensues. Decorin mediated antagonism of Met 
specifically leads to a non-canonical repression of β-catenin and Myc40. HGF, signaling via Met, 
enhances β-catenin stability by two distinct modes including direct phosphorylation of β-catenin47 and 
concomitant repression of glycogen synthase kinase 3β (GSK3β) via phosphorylation. This is an 
example of RTK-mediated stabilization of β-catenin independent of traditional Wnt signaling. 
Collectively, this cascade promotes nuclear translocation of β-catenin which drives transcription of 
              Decorin Roles in Cancer 
 8
prosurvival and protumorigenic genes10. Myc, a target of β-catenin and downstream of HGF/Met1, 
coordinates large networks conducive to growth and proliferation. Interestingly, among the repertoire 
of Myc targets is AP4, a transcriptional repressor of p21WAF148, a cyclin-dependent kinase inhibitor that 
is specifically induced by decorin treatment of various cancer cells1. Conversely, addition of 
exogenous decorin induces a profound and maintained suppression of β-catenin and Myc leading to 
inhibition of several key Met-mediated pathways including migration, proliferation, survival, and 
scattering. This is in part mediated by relieving RTK inhibition of GSK3β, which in turn phosphorylates 
Myc at specific sites40. Phosphorylation of Thr58 on Myc by GSK3β is known to evoke Myc 
degradation via the proteasome. Notably, phosphorylation at this site is markedly induced by soluble 
decorin protein core coincident with nuclear translocation, and 26S proteasomal degradation40. It is 
tempting to speculate that protein phosphatase 2A, the serine-threonine phosphatase directly 
opposing GSK3β, might also be attenuated thereby allowing for enhanced β-catenin and Myc 
degradation. This would lead to de-repression and subsequent induction of the p21 locus while 
providing a mechanism for growth arrest (Fig. 2). Additionally, β-catenin drives cyclin D1 expression 
and this pathway is also antagonized by decorin40. 
Recently, a physical interaction between the armadillo repeats 10-11 of β-catenin with the 
forkhead domain of FoxM1 was identified as crucial for Wnt3a-directed β-catenin nuclear translocation 
and assembly of the ternary complex on promoters of target genes49. Hyperactivation of FoxM1 
occurs primarily in various gastrointestinal tumors50 where it is now believed to facilitate aberrant β-
catenin activation. This is intriguing insofar as decorin-null mice exhibit abnormal intestinal tumor 
formation when exposed to a western diet, and show increased levels of β-catenin26. It is thus 
plausible that decorin in the intestine represents a safeguard against improper activity of the FoxM1/β-
catenin signaling axis.  
A connection might exist between decorin and a genomically-imprinted tumor suppressor known 
as paternally-expressed gene 3 (Peg3). First, morpholino-induced depletion of decorin in a zebrafish 
model results in stunted head-to-tail growth strongly suggesting a role for decorin in regulating 
convergent extension51, a fundamental developmental process mediated primarily by β-catenin 
signaling via the planar cell polarity pathway. Interestingly, Peg3 decreases β-catenin expression 
thereby inhibiting zebrafish tail development in a Wnt-dependent manner52, therefore indicating a 
possible relationship between decorin and Peg3. This connection is further reinforced by the 
observation that the molecular interaction between the Peg3 N-terminal domain and β-catenin is the 
basis for the GSK3β-independent antagonism of β-catenin signaling52. This is very analogous to the 
GSK3β, Wnt independent antagonism of β-catenin protein orchestrated by decorin via Met in various 
tumor cell lines. In the context of tumor progression, this potential link between decorin and non-
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canonical β-catenin attenuation might prove crucial since there is a strong inverse association 
between decreased Peg3 mRNA expression and glioblastoma progression and grade52. 
A new study has evaluated the role of Wnt signaling in promoting a supportive hematopoietic 
niche for stem cell and progenitor development53. Importantly, Wnt3a was found to potently and 
consistently induce decorin expression in co-culture models. Further, it was demonstrated that 
mesenchymal stem cells, derived from the bone marrow, acts as decorin producing cells53. 
Surprisingly, decorin seems to phenocopy almost all the same biological effects of Wnt3a including 
stimulation of c-Kit expression, block of B-cell lymphopoiesis, and maintenance of undifferentiated 
hematopoietic stem/progenitor cells53. These data indicate an intricate role of decorin in modulating 
the hematopoietic microenvironment by mimicking, instead of opposing, in a non-canonical fashion, 
downstream effects promoted by canonical Wnt signaling.  
 
Decorin Affects the Angiogenic Network 
A key step in malignant tumor progression is neo-vascularization beginning with activation of the 
angiogenic switch. The molecular components and mechanisms involved are starting to come into 
clear focus. However, the role of decorin in tumor angiogenesis is quite controversial, with studies 
indicating a pro-angiogenic role such as enhanced endothelial cell migration via increased α2β1 
integrin interaction with collagen type I42.  However, a recent study has clearly shown an inhibitory and 
high-affinity binding of decorin to the vascular endothelial receptor 2 VEGFR243. The intricacies of 
decorin in regulating angiogenesis are even more complex in the cornea, where pro-54 and anti-
angiogenic roles55 exist. Again, we stress the fact that these studies reporting pro-angiogenic activity 
of decorin are typically seen in normal, non-tumorigenic settings. In contrast, as it pertains to tumor 
angiogenesis, decorin, applied as an exogenous or endogenous agent, exerts powerful angiostatic 
activities to curtail vascularization in a variety of tumor cell lines56 and inversely correlates with the 
extent of vascularization57.  
Stromal decorin is able to directly abrogate the HGF/Met signaling axis to inhibit VEGF mediated 
angiogenesis58 by transcriptionally repressing hypoxia inducible factor-1α (HIF-1α), β-catenin, Myc, 
and SP1 under normoxia, and non-canonically suppressing HIF-1α protein 58. This net repression of 
critical transcription factors impairs HGF/Met-driven VEGFA. Further, Sp1 requires p42/44 mitogen-
activated protein kinase (MAPK)-dependent phosphorylation for competent localization and activation 
of VEGF transcription, which is presumably attenuated via RTK antagonism40,58. Further repression of 
VEGF occurs through the attenuation of matrix metalloproteinase (MMP) 2 and 9 transcription which 
also depends on β-catenin. This disallows matrix-bound VEGFA from engaging VEGFR2 on 
endothelial cell surfaces58. 
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Abrogation of HGF/Met in vivo provides mechanistic evidence for the action of decorin. In stark 
contrast to HGF, which promotes angiogenesis through positive VEGF and negative thrombospondin 
regulation59, decorin retards angiogenesis by negative VEGFA and positive thrombospondin 
regulation. Indeed, in vivo studies, decorin can subvert HGF signaling through Met to achieve reduced 
tumor vascularization and vessel density58.   
Through degradation of β-catenin and HIF-1α, several intertwined feedback loops are interrupted. 
Potent loss of HIF-1α results in reduced expression of Met58,60 thus compromising the ability of tumor 
cells to respond to HGF signaling. This is further enhanced by the well documented notion that 
HGF/Met potentiates β-catenin signaling and Myc expression1. Thus, decorin silences this important 
feedback loop for sustained cellular growth while mitigating the overall migratory, proliferative, and 
angiogenic capacity of malignant cells. Collectively, these findings indicate a tripartite attack on the 
Met including ectodomain shedding37 despite TIMP3 induction, caveolin-mediated endocytosis and 
degradation40, and disruption of positive feedback loops58. This is of paramount importance since 
decorin is only one of two known mammalian ligands for Met, the third being internalin B, a bacterial 
protein39.  
Decorin can simultaneously induce endogenous angiogenic inhibitors such as TIMP3 and 
thrombospondin-1, which act to enhance the blockade of VEGF signaling via HGF/Met (Fig. 2), 
consistent with suppressing Met activation to alleviate thrombospondin-159. The ramifications and 
implications of normoxic attenuation of HIF-1α open multiple possibilities of modulating pertinent 
pathways that are active in the early stages of tumor development by circumventing the angiogenic 
switch from being engaged. An intriguing possibility relates to HIF-1α in orchestrating a metabolic 
adaptation that drives tumor vascularization, thus linking decorin to possibly modulate tumor 
metabolism prior to the onset of angiogenesis at early normoxic stages.   
 
Relatives of Decorin in Tumorigenesis: Lumican and Bigylcan 
Related members of the SLRP family include lumican (class II) and biglycan (class I) and share 26% 
and 57% homology with decorin, respectively. Lumican is a keratan sulfate proteoglycan normally 
found within the cornea.  It was recently discovered that lumican is highly expressed within the stroma 
of high-grade breast cancers, while exhibiting an altered expression pattern in various other tumor 
types1. Interestingly, the biological and prognostic correlates of lumican, classified as either a pro- or 
anti-oncogenic agent, within the varied tumors is certainly diversified as specific tumors (colorectal, 
pancreatic, and pulmonary) exhibit a poor prognostic outcome as lumican expression increases within 
the stroma, which is typically indicative of advanced tumors. However, in the case of osteosarcoma 
and melanoma, decreased lumican expression correlates with increased tumor progression1, 
suggesting lumican is anti-oncogenic. This apparent discrepancy for lumican function among different 
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tumor types is reminiscent of the context-dependent function of decorin in angiogenesis, thus, 
highlighting the complex intricacies of SLRPs in tumorigenesis. 
Lumican induces cell cycle arrest by inducing the cyclin-dependent kinase inhibitor p21, 
decreasing the activity and abundance of multiple cyclins, including cyclin-D1, and activates pro-
apoptotic pathways61 akin to decorin. Further, lumican evokes anti-metastatic properties via high-
affinity binding to the α2 I domain of the α2β1 integrin, thus suggesting a mechanism of action. In 
parallel, decorin binds to and antagonizes Met resulting in decreased migratory capacity, impaired 
cellular proliferation and survival. Finally, lumican and decorin are both capable of inhibiting 
metastasis35,36,62. 
Biglycan, the most closely related SLRP family member to decorin, has a very limited involvement 
in cancer progression. Primarily pro-inflammatory via TLR2/4 signaling, a study has implicated 
biglycan overexpression within human pancreatic cancer tissue is accompanied by a concomitant 
induction of p27 and decrease in cyclin A and PCNA63, thereby resulting in an inhibition of tumor 
growth. Despite the relatively high degree of homology, it is interesting that decorin and biglycan do 
not have more extensive overlapping functions in tumorigenesis.  
 
Conclusions and Perspectives 
Decorin, an archetypical small leucine-rich proteoglycan, possesses intrinsic and potent anti-
tumorigenic capabilities. Initially having been characterized as an avid binding partner of collagen and 
inherent regulator of fibrillogenesis, soluble decorin is now emerging as a pan-RTK inhibitor coincident 
with powerful downstream signaling attenuation. Due to its highly-promiscuous and broad binding 
repertoire with extracellular matrix constituents, growth factors and cell surface receptors, decorin can 
be considered a “guardian from the matrix”. Decorin functions as a guardian in the context of 
constraining the activity of a multitude of growth factors, receptor tyrosine kinases, and extracellular 
matrix components. The source of decorin bioactivity lies within this unique attenuation of potent 
growth signals and cues that would otherwise facilitate malignant transformation. Further, in most 
cases, these direct protein interactions act to ameliorate and counteract the overall tumorigenicity of 
the surrounding tumor microenvironment that would otherwise foster and promote malignant 
transformation and tumor progression. Thus, decorin, and perhaps other structurally related SLRPs, 
act at the crossroad between inflammation and cancer and could be determinant players in 
combatting many forms of solid tumors where RTKs are deregulated64.    
Additionally, we would like to draw a comparison between decorin action from outside the cells 
with that of transcription factors acting inside the cells. Several transcription factors such as p53 and 
Myc coordinately regulate the expression of large subsets of genes crucial for the viability of cellular 
processes, whereas decorin regulates growth factor bioavailability and receptor modulation within the 
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extracellular milieu. Notably, a genetic cooperation between decorin and the tumor suppressor p53, 
which has been widely regarded as the “guardian of the genome”, has been already established 
insofar as germline null mutations in decorin and p53 genes cause enhanced lymphoma 
tumorigenesis65. Thus, it is plausible to connect stromal decorin to the intracellular regulation of the 
expression of a large genetic network.  
One of the challenges of future research is finding and isolating the leucine-rich repeats of decorin 
that harbor distinct bioactivities. This could be of great clinical interest as adjuvant peptide therapy. 
Further engineering of these smaller domains to specifically target cognate receptors could underlie 
advanced therapeutic drug designs and serve as a potent addition to the growing armamentarium of 
matrix-derived cancer modalities.  
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Figure Legends 
 
Figure 1: Decorin interactome encompassing growth factors, receptors, and putative extracellular 
matrix components to which decorin physically, through high affinity interactions, binds and regulates 
either negatively or positively. Please refer to the text for additional details. 
 
Figure 2: Broad receptor antagonism and attenuation of downstream signaling cascades mediated by 
decorin in tumor cells. Anti-proliferative, immunomodulatory, and anti-angiogenic properties are 
regulated following engagement of decorin to cell surface receptors. Please refer to the text for a 
detailed discussion of pathway modulation.  
 


